View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsKhosla Ventures Acquisition 将来の成長Future 基準チェック /06現在、 Khosla Ventures Acquisitionの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Capital Markets 収益成長12.4%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Dec 22Khosla Ventures Acquisition Co. Files Form 15Khosla Ventures Acquisition Co. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Class A Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Class A Common Stock was $0.0001 per share.お知らせ • Dec 13Khosla Ventures Acquisition Co.(NasdaqCM:KVSA) dropped from NASDAQ Composite IndexKhosla Ventures Acquisition Co. has been dropped from NASDAQ Composite Index .お知らせ • Aug 25Khosla Ventures Acquisition Receives Non-Compliance Letter from NasdaqOn August 18, 2023, Khosla Ventures Acquisition Co. (the Company") received a letter (the Nasdaq Letter") from the Listing Qualifications staff of The Nasdaq Stock Market LLC (Nasdaq") notifying the Company that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(2), which requires that the Company's listed securities maintain a minimum Market Value of Listed Securities (MVLS") of $35 million. The Nasdaq Letter further provided that, pursuant to Nasdaq Listing Rule 5810(c)(3)(C), the Company is entitled to a compliance period to regain compliance with Nasdaq Listing Rule 5550(b)(2), which compliance period will expire on February 14, 2024. Anytime during the compliance period described above, the company's MVLS must close at $35 million or more for a minimum of ten consecutive business days, at which point Nasdaq will provide the Company with written confirmation of compliance. The Company is working to comply with Nasdaq's MVLS requirements as set forth in the Nasdaq Listing Rule 5550(b)(2) within the compliance period provided by Nasdaq.New Risk • Aug 18New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$73.0m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$7.0m). Revenue is less than US$1m. Minor Risks Less than 3 years of financial data is available. Large one-off items impacting financial results. Market cap is less than US$100m (US$73.0m market cap).お知らせ • Apr 03Khosla Ventures Acquisition Co. announced delayed annual 10-K filingOn 04/01/2022, Khosla Ventures Acquisition Co. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Feb 15Khosla Ventures Acquisition Co. Announces Resignation of Jagdeep Singh from the BoardOn February 10, 2022 Jagdeep Singh notified the Board of Directors of Khosla Ventures Acquisition Co. of his resignation from the Board and all committees thereof, effective immediately.お知らせ • Sep 01Khosla Ventures Acquisition Co. Receives Expected Notice from Nasdaq Regarding Delayed Quarterly ReportKhosla Ventures Acquisition Co. announced August 31, 2021 that, on August 25, 2021, it received a notice ("Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule") because the Company failed to timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 (the "Form 10-Q") with the Securities and Exchange Commission ("SEC"). The Notice has no immediate effect on the listing or trading of the Company's securities on the Nasdaq Capital Market. As previously disclosed in the Form 12b-25 filed on August 16, 2021 by the Company with the SEC, the Company was unable to file the Form 10-Q by the required due date of August 16, 2021. The Company intends to file the Form 10-Q with the SEC as soon as practicable.お知らせ • Aug 17Khosla Ventures Acquisition Co. announced delayed 10-Q filingOn 08/16/2021, Khosla Ventures Acquisition Co. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jun 10Valo Health, LLC entered into an agreement to acquire Khosla Ventures Acquisition Co. (NasdaqCM:KVSA) from Khosla Ventures SPAC Sponsor LLC and others in a reverse merger transaction for $2.3 billion.Valo Health, LLC entered into an agreement to acquire Khosla Ventures Acquisition Co. (NasdaqCM:KVSA) from Khosla Ventures SPAC Sponsor LLC and others in a reverse merger transaction for $2.3 billion on June 9, 2021. Under the terms of the agreement, Valo Health will get 225 million Class A common stock of Khosla Ventures. In addition, on June 9, 2021, concurrently with the execution of the merger agreement, Khosla Ventures entered into subscription agreements pursuant to which investors have collectively subscribed for approximately 16.85 million shares of Khosla Ventures common stock for an aggregate purchase price equal to $168.5 million. Post the transaction, existing Valo rollover equity would be 80%, subscription investors will hold 8%, Khosla Ventures public shares will constitute 10%, and Khosla Ventures sponsor shares will constitute 2%. Upon closing, Khosla Ventures Acquisition will immediately be renamed Valo Health, Inc. Samir Kaul, Founding Partner and Managing Director at Khosla Ventures to join Valo’s Board of Directors following the completion of the business combination. The Board of Directors Khosla Ventures Acquisition has unanimously approved the transaction and Boards of Directors of Valo has approved the transaction. The transaction is subject to approval of the stockholders of Khosla Ventures and equity holders of Valo; effectiveness of the proxy statement / registration statement on Form S-4 to filed in connection with transaction; expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act; receipt of approval for listing on the Nasdaq Stock Market the shares of Khosla Ventures to be issued in connection with the merger; Khosla Ventures have at least $5,000,001 of net tangible assets upon closing; and he completion of the Pre-Closing Restructuring no later than one business day prior to the closing. The closing of this transaction is expected to occur in the third quarter of 2021. Jim Morrone and Luke J. Bergstrom of Latham & Watkins LLP acted as legal advisors to Khosla Ventures. Joseph C. Theis and Stuart M. Cable of Goodwin Procter LLP acted as legal advisors, and, J.P. Morgan Securities LLC acted as financial advisor to Valo. J.P. Morgan Securities LLC acted as Khosla Ventures' sole placement agent for the subscription agreement. Cooley LLP is acting as legal counsel to the placement agent.お知らせ • May 19Khosla Ventures Acquisition Co. announced delayed 10-Q filingOn 05/18/2021, Khosla Ventures Acquisition Co. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Khosla Ventures Acquisition は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NasdaqCM:KVSA - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/2023N/A588N/A6/30/2023N/A699N/A3/31/2023N/A477N/A12/31/2022N/A244N/A9/30/2022N/A-1-1-1N/A6/30/2022N/A-1-1-1N/A3/31/2022N/A-3-2-2N/Aアナリストによる今後の成長予測収入対貯蓄率: KVSAの予測収益成長が 貯蓄率 ( 2.2% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: KVSAの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: KVSAの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: KVSAの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: KVSAの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: KVSAの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YDiversified-financials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/12/13 05:43終値2023/12/11 00:00収益2023/09/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Khosla Ventures Acquisition Co. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Dec 22Khosla Ventures Acquisition Co. Files Form 15Khosla Ventures Acquisition Co. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Class A Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Class A Common Stock was $0.0001 per share.
お知らせ • Dec 13Khosla Ventures Acquisition Co.(NasdaqCM:KVSA) dropped from NASDAQ Composite IndexKhosla Ventures Acquisition Co. has been dropped from NASDAQ Composite Index .
お知らせ • Aug 25Khosla Ventures Acquisition Receives Non-Compliance Letter from NasdaqOn August 18, 2023, Khosla Ventures Acquisition Co. (the Company") received a letter (the Nasdaq Letter") from the Listing Qualifications staff of The Nasdaq Stock Market LLC (Nasdaq") notifying the Company that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(2), which requires that the Company's listed securities maintain a minimum Market Value of Listed Securities (MVLS") of $35 million. The Nasdaq Letter further provided that, pursuant to Nasdaq Listing Rule 5810(c)(3)(C), the Company is entitled to a compliance period to regain compliance with Nasdaq Listing Rule 5550(b)(2), which compliance period will expire on February 14, 2024. Anytime during the compliance period described above, the company's MVLS must close at $35 million or more for a minimum of ten consecutive business days, at which point Nasdaq will provide the Company with written confirmation of compliance. The Company is working to comply with Nasdaq's MVLS requirements as set forth in the Nasdaq Listing Rule 5550(b)(2) within the compliance period provided by Nasdaq.
New Risk • Aug 18New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$73.0m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$7.0m). Revenue is less than US$1m. Minor Risks Less than 3 years of financial data is available. Large one-off items impacting financial results. Market cap is less than US$100m (US$73.0m market cap).
お知らせ • Apr 03Khosla Ventures Acquisition Co. announced delayed annual 10-K filingOn 04/01/2022, Khosla Ventures Acquisition Co. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Feb 15Khosla Ventures Acquisition Co. Announces Resignation of Jagdeep Singh from the BoardOn February 10, 2022 Jagdeep Singh notified the Board of Directors of Khosla Ventures Acquisition Co. of his resignation from the Board and all committees thereof, effective immediately.
お知らせ • Sep 01Khosla Ventures Acquisition Co. Receives Expected Notice from Nasdaq Regarding Delayed Quarterly ReportKhosla Ventures Acquisition Co. announced August 31, 2021 that, on August 25, 2021, it received a notice ("Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule") because the Company failed to timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 (the "Form 10-Q") with the Securities and Exchange Commission ("SEC"). The Notice has no immediate effect on the listing or trading of the Company's securities on the Nasdaq Capital Market. As previously disclosed in the Form 12b-25 filed on August 16, 2021 by the Company with the SEC, the Company was unable to file the Form 10-Q by the required due date of August 16, 2021. The Company intends to file the Form 10-Q with the SEC as soon as practicable.
お知らせ • Aug 17Khosla Ventures Acquisition Co. announced delayed 10-Q filingOn 08/16/2021, Khosla Ventures Acquisition Co. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 10Valo Health, LLC entered into an agreement to acquire Khosla Ventures Acquisition Co. (NasdaqCM:KVSA) from Khosla Ventures SPAC Sponsor LLC and others in a reverse merger transaction for $2.3 billion.Valo Health, LLC entered into an agreement to acquire Khosla Ventures Acquisition Co. (NasdaqCM:KVSA) from Khosla Ventures SPAC Sponsor LLC and others in a reverse merger transaction for $2.3 billion on June 9, 2021. Under the terms of the agreement, Valo Health will get 225 million Class A common stock of Khosla Ventures. In addition, on June 9, 2021, concurrently with the execution of the merger agreement, Khosla Ventures entered into subscription agreements pursuant to which investors have collectively subscribed for approximately 16.85 million shares of Khosla Ventures common stock for an aggregate purchase price equal to $168.5 million. Post the transaction, existing Valo rollover equity would be 80%, subscription investors will hold 8%, Khosla Ventures public shares will constitute 10%, and Khosla Ventures sponsor shares will constitute 2%. Upon closing, Khosla Ventures Acquisition will immediately be renamed Valo Health, Inc. Samir Kaul, Founding Partner and Managing Director at Khosla Ventures to join Valo’s Board of Directors following the completion of the business combination. The Board of Directors Khosla Ventures Acquisition has unanimously approved the transaction and Boards of Directors of Valo has approved the transaction. The transaction is subject to approval of the stockholders of Khosla Ventures and equity holders of Valo; effectiveness of the proxy statement / registration statement on Form S-4 to filed in connection with transaction; expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act; receipt of approval for listing on the Nasdaq Stock Market the shares of Khosla Ventures to be issued in connection with the merger; Khosla Ventures have at least $5,000,001 of net tangible assets upon closing; and he completion of the Pre-Closing Restructuring no later than one business day prior to the closing. The closing of this transaction is expected to occur in the third quarter of 2021. Jim Morrone and Luke J. Bergstrom of Latham & Watkins LLP acted as legal advisors to Khosla Ventures. Joseph C. Theis and Stuart M. Cable of Goodwin Procter LLP acted as legal advisors, and, J.P. Morgan Securities LLC acted as financial advisor to Valo. J.P. Morgan Securities LLC acted as Khosla Ventures' sole placement agent for the subscription agreement. Cooley LLP is acting as legal counsel to the placement agent.
お知らせ • May 19Khosla Ventures Acquisition Co. announced delayed 10-Q filingOn 05/18/2021, Khosla Ventures Acquisition Co. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.